Purdue Institute for Drug Discovery

OTL-78

Overview: 

Prostate-specific membrane antigen (PSMA)-targeted near infrared dye for fluorescence-guided surgery of prostate cancer.

Status: 

Purdue Faculty: 

Dr. Philip Low

Development Partner: 

OnTarget Laboratories

Clinical Trials: 

A phase 1a/1b/2a study to assess the safety, tolerability and pharmacokinetics of OTL78, a PSMA-targeted fluorescent agent, for the intraoperative imaging of prostate cancer

Research Articles: 

Development of Tumor-Targeted Near Infrared Probes for Fluorescence Guided Surgery

First-in-patient study of OTL78 for intraoperative fluorescence imaging of prostate-specific membrane antigen-positive prostate cancer: a single-arm, phase 2a, feasibility trial